Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
GenMark Diagnostics performs board shuffle
February 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing genmark diagnostics, lisa giles, michael kagnoff
US diagnostic systems provider GenMark Diagnostics has named two new board members whilst announcing a resignation. Lisa Giles (pictured) who …
Eisai cancer drug performs in sarcoma disease
February 26, 2015Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour
Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …
AstraZeneca enters autoimmune diseases pact with Orca
February 25, 2015Research and Development, Sales and Marketing AstraZeneca, autoimmune, orca, orphan nuclear receptor gamma inhibitors, psoriasis, retinoic
AstraZeneca has signed a three-year research deal with the UK-based biotech firm Orca to develop treatments for autoimmune diseases. The …
Napp launches biosimilar in UK
February 25, 2015Research and Development, Sales and Marketing Hospira, Napp, Remicade, anti-TNF biologic, biosimilar, infliximab, remsima
Napp Pharmaceuticals has launched its own biosimilar version of an anti-TNF biologic in Europe paving the way for patient access …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
UCB’s new chief executive picked as EU rep for MISG
February 25, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jean-Christophe Tellier, MISG, UCB
UCB’s newly-appointed chief executive Jean-Christophe Tellier has been selected to join the Ministerial Industry Strategy Group (MISG). Elected to the …
Shire to buy Meritage Pharma
February 25, 2015Research and Development, Sales and Marketing AbbVie, Meritage Pharma, Shire, eoe, gastrointestinal
Shire has purchased Meritage Pharma, a privately-held company specialising in gastrointestinal and skin diseases for $70 million. The acquisition means …
Doctors appeal to prescribe Avastin off-label
February 25, 2015Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD
NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Takeda acquires Turkish firm Neutec
February 24, 2015Sales and Marketing Takeda, Turkey, gastroenterology, neutec, respiratory, turkish
Takeda has signed an agreement to acquire one of Turkey’s leading pharma firms Neutec in a $120 million deal. The …
Merck puts HIV drug in shared patent pool
February 24, 2015Research and Development, Sales and Marketing AbbVie, Gilead, HIV, Merck, Raltegravir, Roche, isentress
Merck is teaming up with the Medicines Patent Pool (MPP) to license its paediatric HIV treatment in developing countries. The …
Novel device could help fight kidney disease
February 24, 2015Research and Development, Sales and Marketing Bio Nano Consulting, Pfizer, QELFA, Rapamune, device, ime, kidney
A novel device that combines nanotechnology and a pregnancy tester could help treat kidney disease, according to a report by …
BMS in $1.5 billion immuno-oncology expansion
February 24, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Rigel, flexus, immuno-oncology
Bristol-Myers Squibb has confirmed two major deals to enhance the company’s standing in the immuno-oncology field. The first agreement sees …
WuXi PharmaTech borrows to expand
February 24, 2015Manufacturing and Production, Sales and Marketing China, NextCODE Health, WuXi PharmaTech, XenoBiotic Laboratories, philadelphia
WuXi PharmaTech has kick started a syndicated loan arrangement in order to borrow up to $165 million from a consortium …
Algatech gets new chief executive and chief scientist
February 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Algatech, Ronnie Meninger, Sammy Boussiba
Israel-based biotech Algatech has confirmed the appointment of Ronnie Meninger as its chief executive, and Sammy Boussiba as chief scientist. Meninger (pictured) …
Merck invests $450m in NGM Biopharma
February 23, 2015Sales and Marketing Merck, NGM Biopharma, NP201, diabetes, nonalcoholic steatohepatitis, obesity
Merck is to collaborate on drug development with biotech firm NGM Pharmaceuticals in a $450 million deal. The collaboration will …
Priority review for Pfizer’s lung drug
February 23, 2015Sales and Marketing FDA, Pfizer, Rapamune, lung, lymphangioleiomyomatosis, sirolimus
The US Food and Drug Administration FDA has accepted Pfizer’s lung drug Rapamune for priority review. Rapamune (sirolimus) prevents organ …
Chiesi’s stem cell therapy approved in Europe
February 23, 2015Research and Development, Sales and Marketing Chiesi, EC, Europe, Holoclar, Holostem Advanced Therapies, LSCD, stem cell
Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
